Insomnia Therapeutics - Pipeline Assessment and Market Forecasts to 2018

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) November 24, 2011 -- GlobalData estimates that the global insomnia therapeutics market was worth $918m in 2010 and will grow at a Compound Annual Growth Rate (CAGR) of 4.9% to reach $1,343m by 2018. This steady growth is primarily attributed to the expected launch of pipeline products in 2014 (such as Intermezzo, tasimelteon and MK-4305 in the G7 countries, the launch of SEP-190 (eszopiclone) in Japan and the launch of ramelteon in Europe). Increasing awareness and treatment seeking rates for insomnia are expected to further contribute to the growth of the market. The impact of the patent expiry of Lunesta

(eszopiclone) in 2014, an approved drug for chronic insomnia in the US, is expected to be minimal due to the launch of pipeline drugs in the same year.

The global insomnia therapeutics market currently has non-benzodiazepines (zolpidem, zaleplon and Lunesta), selective melatonin receptors (ramelteon), benzodiazepines (triazolam, temezapam and estazolam), Over The Counter (OTC) (vitamin and melatonin supplements) and off label drugs (trazodone, mitrazepine, amytriptyline) all of which have moderate levels of safety and efficacy. Lunesta is the only approved medication for chronic insomnia. Insomnia is prevalent in all ages of the population but the currently marketed drugs are not been approved for all age groups. The insomnia therapeutics market is therefore moderately successful in meeting the market demand.

The developmental pipeline for insomnia is strong with 20 molecules in various Phases of development.
The pipeline mainly includes Gaba-AminoButrytic Acid receptors (GABAA), -AminoButrytic Acid- Benzodiazepine binding sites (GABA-BZ), receptor antagonists, selective melatonin receptor antagonists,

orexin receptor antagonists, histamine and dopamine receptor agonists, low dose formulation of zolpidem, experimental formulation of zaleplon and others. The developmental pipeline for insomnia has six First In Class (FIC) molecules, one molecule in Phase III and five in Phase II. MK-4305 in Phase III has the potential to compete with the currently marketed drugs. The effect of patent expiries and the presence of generics in the market are expected to be neutralized by the launch of the late stage pipeline products.

For Sample Pages, please click or add the below link to your browser:
http://globaldata.com/reportstore/RequestSamplePages.aspx?ID=Insomnia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&CompanyID=fprco

The current insomnia therapeutics market has nine approved products for the treatment of insomnia.

Eight of the approved drugs are for the treatment of transient insomnia while only one drug has been approved for chronic insomnia. There is a need for drugs that can be used for chronic insomnia. The available pharmacological treatments for insomnia have moderate safety and efficacy profiles. Physicians and patients alike prefer behavioral therapies to currently available medications due to the adverse effects (abuse potential) associated with them. Hence, there is a high unmet need for medications with better safety and efficacy profiles.

GlobalData, the industry analysis specialist, has released its new report, “Insomnia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global insomnia market. The report identifies the key trends shaping and driving the global insomnia market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global insomnia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://globaldata.com/reportstore/Report.aspx?ID=Insomnia-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2018&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthca&CompanyID=fprco

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533

Asia Pacific: +91 40 6616 6782

Insomnia Therapeutics     Pharmaceuticals and Healthcare